Clinical trial NCT04933461: Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)
Official title: Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Accident Injury
Keywords: safety lancet
capillary blood sampling
accidental needle-stick injury
Lead sponsor: HTL-Strefa S.A.
Sponsor class: INDUSTRY
First posted: 2021-06-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: A simulated clinical use testing to evaluate the Medlance Plus and myLance sharps injury prevention feature in accordance with the FDA's guidance on medical devices with sharps injury prevention features.

Detailed description: This study aims to evaluate the safety of the use of the following safety lancets: Medlance Plus and myLance in the prevention of needle-stick injury (NSI) and to evaluate the user's opinion with regard to the handling characteristics of the medical devices.

The simulated use clinical study involves healthcare professionals (HCPs) who routinely use safety lancets to collect blood samples.

Eligibility criteria: Inclusion Criteria:

* evaluators who routinely use safety lancets to collect capillary blood samples (prevention of the learning curve artifacts)
* evaluators will be United States (US) residents
* evaluators can read, write, and speak English
* evaluators are at least 18 years old
* evaluators are able to understand and provide signed consent for the study
* evaluators are willing to comply with the study protocol, including being willing to answer questions and complete questionnaires.
* evaluators have no concerns about the ability to perform the simulated skin pricking.

Exclusion Criteria:

* evaluators who do not routinely use safety lancets to collect capillary blood samples,
* evaluators who cannot read, write, and speak English,
* evaluators or a family member have a business or consulting relationship with a pharmaceutical or medical device company, or
* evaluators who have participated in a product evaluation or marketing study involving safety lancets within the last six months

Primary outcomes:
measure: The true failure rate of the tested devices.
timeFrame: At time of testing, up to 90 minutes
measure: Effectiveness of the safety lancet's sharps injury prevention features.
timeFrame: At time of testing, up to 90 minutes
Secondary outcomes:
measure: Evaluation of the safety of the devices based on the evaluators' assessments.
timeFrame: At time of testing, up to 90 minutes ]
measure: Evaluation of various aspects of the ease of use.
timeFrame: At time of testing, up to 90 minutes ]
measure: Detection of any handling, usability questions / issues associated with the device.
timeFrame: At time of testing, up to 90 minutes ]
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Chicago office
state: Illinois
city: Boston
country: United States
facility: Boston office
state: Massachusetts
Study officials:
References: